Maegan Fuller writes that the role of inter partes review (IPR) proceedings will only increase in the intellectual property battles of the pharmaceutical industry. With the influx of IPRs come new issues and new questions not anticipated by the drafters of the Hatch-Waxman Act.
General Publications
November 30, 2015
“Inter Partes Review and the Pharmaceutical Industry: A New Normal,” New Jersey Law Journal, November 30, 2015.
Media Contact